This text has been automatically translated, it may contain errors or inaccuracies.
MEDICINES
Favorite
Remove from my list

The Council of Ministers has adopted a new law to prevent drug shortages

After the holidays, this new rule will begin proceedings in the Congress of Deputies so that it can enter into force. In addition to avoiding shortages, the law seeks to increase patient savings through a new pricing system.

MADRID, 21/07/2026.-  El minsitro de Industria y Turismo, Jord Hereu (i); la vicepresidenta segunda y ministra de Trabajo y Economía Social, Yolanda Díaz (2i); la ministra de Inclusión, Seguridad Social y Migraciones y portavoz del Gobierno de Industria y Turismo, Elma Saiz (2d), y la ministra de Sanidad, Mónica García (d) durante la rueda de prensa posterior a la reunión del Consejo de Ministros, este martes en el Palacio de La Moncloa. EFE/ J.J.Guillen
Press conference following the Council of Ministers. Photo: EFE.

On Tuesday, the Council of Ministers approved the preliminary draft of the Medicines and Pharmaceuticals Act, a new regulation that will bring many new developments to the current one, including measuresto prevent shortages   or a new pricing system that will save the patient.

The draft will now begin to be processed in Congress and, if it is approved and entered into force in the Courts, it will replace the regulatory framework in force since 2015.

At the press conference following the Council of Ministers, the Minister of Health, Mónica García, pointed out that the law "responds to everyday situations" such as how long a patient needs to access new medicines or how to respond to a lack of drug supply.

Guarantee of supply

One of the main innovations is to ensure the supply of medicines, for which the new law introduces the concept of "strategic medicine", a drug deemed essential but whose supply is uncertain.

The Act shall empower the Spanish Agency for Medicinal Products and Medical Products to take economic and regulatory measures to ensure its permanent presence on the market.

New pricing system

In order to ensure savings, two additional pricing systems will be established and a medicinal product cannot be present in either system simultaneously.

On the one hand, there will be a reference pricemodel , which, as hitherto, will be the general framework for setting ceilings for homogeneous groups of equivalent medicines (containing the same active ingredient and the same method of intake), which are reviewed annually to strengthen the structural savings of the system.

On the other hand, adynamic price system has been created for off-patent drugs (generic, hybrid or biosimilar) , which can be adjusted gradually and automatically as the distribution volume increases.

Moreover, among medicines containing the same active ingredient, there may be several at different prices, so that the patient may choose a higher price mark by paying the difference from the lowest price in the group.

New drugs

The new law allows for the early introduction into the public health system of certain innovative medicines that meet an unresolved medical need or an urgent clinical need.

During the interim period, patients will be used and the results will be monitored, and if the expected benefit is confirmed, funding will be fixed, but if the results are not expected, the laboratory will have to make compensation.

New Prescription Powers

At the time of the adoption of the regulation, certain professionals (nurses, physiotherapy professionals) who have hitherto been unable to prescribe the use of medicinal products, as practitioners, dentists and podologists, shall also have the power to prescribe within the scope of their competence.

In order to ensure the effectiveness of this measure, the regulatory framework must be updated within one year, and interdisciplinary protocols designed to facilitate operational coordination between professionals must be drawn up and published.

Rational use of medicines

For the first time, the bill introduces the rational use of medicines and medical devices into a comprehensive framework and takes it as a guiding principle of pharmaceutical policy.

The aim of the rule is to ensure that each patient receives the treatment best suited to their clinical needs, at the right dose, for the necessary time and at the lowest possible cost to both the patient and society.

You might like

Load more
Advertising
X